Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.

Clinical trials are the backbone of medical innovations, shaping the therapies and diagnostics that define modern healthcare. Designing and executing a successful trial involves more than scientific ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...